Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast‑enhanced magnetic resonance imaging

Zhai,Jian; Zheng,Wenqiang; Zhang,Qin; Wu,Jiangfen; Zhang,Xuexi

doi:10.3892/ol.2019.10083

Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast‑enhanced magnetic resonance imaging

Authors:
- Jian Zhai
- Wenqiang Zheng
- Qin Zhang
- Jiangfen Wu
- Xuexi Zhang
View Affiliations

Affiliations: Medical Imaging Centre, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241000, P.R. China, GE Healthcare Life Sciences, Shanghai 200000, P.R. China
Published online on: February 28, 2019 https://doi.org/10.3892/ol.2019.10083
Pages: 4237-4244
Copyright: © Zhai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The value of pharmacokinetic parameters derived from dynamic contrast‑enhanced magnetic resonance imaging (DCE‑MRI) in distinguishing pituitary microadenoma subtypes was investigated in the present study. Pathology and follow‑up outcomes were applied as the gold standard for differentiating between 76 patients with pituitary microadenomas (38 prolactin‑producing tumors, 17 adrenocorticotropic hormone adenomas and 21 growth hormone‑producing tumors) and 20 patients with normal pituitary glands. DCE‑MRI was conducted to obtain the following quantitative permeability parameters: Volume transfer constant (Ktrans), rate constant (Kep) and extracellular extravascular volume fraction (Ve). Among the 76 cases included, 61 were visually diagnosed using conventional MRI. The Ktrans, Kep and Ve of the microadenoma cases were 0.472±0.292/min, 0.765±0.359/min and 0.792±0.345, respectively. The Ktrans, Kep and Ve of the normal control group were 0.902±0.238/min, 1.208±0.599/min and 0.928±0.378, respectively. The Ktrans and Kep of patients with microadenomas were significantly lower compared with those of the normal controls (P<0.05). However, the Ve of the two groups did not significantly differ. Subtype differentiation analysis revealed that patients with growth hormone‑producing tumors exhibited the highest Ktrans value (P<0.05). Kep significantly differed between growth hormone‑producing tumors and the other two subtypes (P<0.05), but did not significantly differ among three subtypes. Receiver‑operator characteristic analysis indicated that the area under the curve values of Ktrans and Kep were 0.884 and 0.728, respectively. Sensitivity and specificity were 95.0 and 82.6%, respectively, when Ktrans was set to 0.614/min as the cut‑off value, and when the Kep cut‑off value was set to 0.985/min, sensitivity and specificity were 60.0 and 81.3%, respectively. In conclusion, Ktrans and Kep derived from DCE‑MRI could be applied to detect and identify microadenoma subtypes. Ktrans better reflects the blood perfusion alterations exhibited by patients with different microadenoma subtypes.

View Figures

View References

1	Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA and Beckers A: High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 91:4769–4775. 2006. View Article : Google Scholar : PubMed/NCBI
2	Lieb JM and Ahlhelm FJ: Tumors of the sellar region. Radiologe. 57:740–747. 2017.(In German). View Article : Google Scholar : PubMed/NCBI
3	Stacey RJ and Powell MP: Sellar and Parasellar Tumors. Neurosurgery. 187–204. 2006.PubMed/NCBI
4	Scheithauer BW, Horvath E, Kovacs K, Laws ER Jr, Randall RV and Ryan N: Plurihormonal pituitary adenomas. Semin Diagn Pathol. 3:69–82. 1986.PubMed/NCBI
5	Shah S, Waldman AD and Mehta A: Advances in pituitary imaging technology and future prospects. Best Pract Res Clin Endocrinol Metab. 26:35–46. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rand T, Lippitz P, Kink E, Huber H, Schneider B, Imhof H and Trattnig S: Evaluation of pituitary microadenom as with dynamic MR imaging. Eur J Radiol. 41:131–135. 2002. View Article : Google Scholar : PubMed/NCBI
7	Kopczak A, Renner U and Karl Stalla G: Advances in understanding pituitary tumors. F1000Prime Rep. 6:52014. View Article : Google Scholar : PubMed/NCBI
8	Murase K: Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med. 51:858–862. 2004. View Article : Google Scholar : PubMed/NCBI
9	Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, et al: Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: Initial results. Magn Reson Imaging. 25:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zhijun Z: Research of DCE-MRI quantitative analysis value in cervical squamous cell carcinomas microvascular permeability. Chin J CT MRI. 13:71–73. 2015.(In Chinese).
11	Lei J, Tian Y, Zhu SC, Han Q, Wei Y, Yang S and Shi DP: Preliminary study of IVIM-DWI and DCE-MRI in early diagnosis of esophageal cancer. Eur Rev Med Pharmacol Sci. 19:3345–3350. 2015.PubMed/NCBI
12	Zhao LY, Zhou CW, Zhang RZ, et al: Correlation of quantitative parameters of dynamic contrast-enhanced MRI with subtypes of breast carcinoma. Chin J Med Imaging Technol. 29:1126–1130. 2013.(In Chinese).
13	Zhao J, Yang ZY, Luo BN, Yang JY and Chu JP: Quantitative evaluation of diffusion and dynamic contrast-enhanced MR in tumor parenchyma and peritumoral area for distinction of brain tumors. PLoS One. 10:e01385732015. View Article : Google Scholar : PubMed/NCBI
14	Yuan A, Lin CY, Chou CH, Shih CM, Chen CY, Cheng HW, Chen YF, Chen JJ, Chen JH, et al: Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS One. 6:e160622011. View Article : Google Scholar : PubMed/NCBI
15	Jia ZZ, Geng DY, Liu Y, Chen XR and Zhang J: Microvascular permeability of brain astrocytoma with contrast-enhanced magnetic resonance imaging: Correlation analysis with histopathologic grade. Chin Med J (Engl). 126:1953–1956. 2013.PubMed/NCBI
16	Jia ZZ, Gu HM, Zhou XJ, Shi JL, Li MD, Zhou GF and Wu XH: The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging. Eur J Radiol. 84:1805–1809. 2015. View Article : Google Scholar : PubMed/NCBI
17	Takada K, Yamada S and Teramoto A: Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocr Pathol. 15:131–139. 2004. View Article : Google Scholar : PubMed/NCBI
18	Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K and Stefaneanu L: Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol. 10:229–235. 1999. View Article : Google Scholar : PubMed/NCBI
19	Tofts PS: Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 7:91–101. 1997. View Article : Google Scholar : PubMed/NCBI
20	Ruimin L, Yajia G, Jian M, et al: Research of benign and malignant breast lesions differentiation using quantitative DCE-MRI. Chin J Radiol. 45:164–169. 2011.(In Chinese).
21	Wang Y, Huang W, Panicek DM, Schwartz LH and Koutcher JA: Feasibility of using limited population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med. 59:1183–1189. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yankeelov TE, Cmn GO, Addison CL, Wallace JC, Wilkins RC, Pappas BA, Santyr GE and Gore JC: Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data. Magn Reson Med. 57:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
23	Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T and Lloyd RV: Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 438:595–602. 2001. View Article : Google Scholar : PubMed/NCBI
24	Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL and Wass JA: Angiogenesis in pituitary adenomas-relationship to endocrine function, treatment and outcome. J Endocrinol. 165:475–481. 2000. View Article : Google Scholar : PubMed/NCBI
25	Onguru O, Casey MB, Kajita S, Nakamura N and Lloyd RV: Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: A review. Endocr Pathol. 16:253–277. 2005. View Article : Google Scholar : PubMed/NCBI
26	Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL and Wass JA: Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab. 85:1159–1162. 2000. View Article : Google Scholar : PubMed/NCBI
27	Jugenburg M, Kovacs K, Stefaneanu L and Scheithauer BW: Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphological study. Endocr Pathol. 6:115–124. 1995. View Article : Google Scholar : PubMed/NCBI
28	Jasek E, Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E and Trela F: Microvessel density and area in pituitary microadenomas. Endocr Pathol. 20:221–226. 2009. View Article : Google Scholar : PubMed/NCBI
29	Jeffcoate WJ, Pound N, Sturrock ND and Lambourne J: Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 45:299–303. 1996. View Article : Google Scholar : PubMed/NCBI
30	Juneau P, Schoene W C and Black P: Malignant tumors in the pituitary gland. Arch Neurol. 49:555–558. 1992. View Article : Google Scholar : PubMed/NCBI
31	Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM, et al: Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab. 84:3823–3830. 1999. View Article : Google Scholar : PubMed/NCBI
32	Lohrer P, Gloddek J, Hopfner U, Losa M, Uhl E, Pagotto U, Stalla GK and Renner U: Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology. 74:95–105. 2001. View Article : Google Scholar : PubMed/NCBI